Modular dual-mobility (MDM) constructs can be used to reduce dislocation rates after total hip replacement (THR). However, there are concerns about adverse reaction to metal debris (ARMD) as a result of fretting corrosion between the metal liner and shell. This systematic review reports outcomes following THR using MDM components. It was registered with PROSPERO and conducted in line with Cochrane and PRISMA recommendations.

Sixteen articles were included overall, with meta-analysis performed on relevant subsets using a random intercept logistic regression model. Estimated median incidence of ARMD requiring revision surgery within study follow-up period was 0.3% (95% CI 0.1 – 1.8%, from 11 cohort studies containing 1312 cases).

Serum metal ion levels were mildly raised in 7.9% of cases, and significantly raised in 1.8%, but there was no correlation with worse clinical hip function scores within studies. Dislocation rate was 0.8%. Revision rate was 3.3%.

There are mixed reports of wear on the backside of the metal liner from the acetabular shell and screw heads. Both implant design and component malseating are implicated, but currently it is unclear to what extent each factor is responsible.

Studies were poor quality with high risk of confounding, especially from trunnion corrosion. We have made recommendations for further work. In the meantime, surgeons should be aware of the potential risk of ARMD when considering using an MDM prosthesis, and, if selecting one, must ensure proper seating of the liner and screws intraoperatively.

Keywords: ALTR; ARMD; arthroplasty; hip replacement; metal; modular dual-mobility

Introduction

Dislocation remains a major challenge following total hip replacement (THR), occurring after 0.5% to 5% of primary and 5% to 30% of revision procedures.1-4 Dual-mobility (DM) constructs are one option for patients deemed at high risk. The concept, pioneered by Bousquet and Rambert in the 1970s, uses two articulating surfaces to combine the stability of a large femoral head with Sir John Charnley’s low-friction arthroplasty principle.5,6 DM constructs comprise a small femoral head articulating within a mobile polyethylene liner, that itself articulates within a fixed acetabular shell. These components improve stability by increasing the head–neck ratio, range of motion, and jump distance.7 Several studies have reported lower dislocation rates with DM implants, most marked in revision arthroplasty.4,8,9

Modular dual-mobility

The original, ‘anatomical’ dual-mobility (ADM) constructs use a monoblock acetabular shell, lacking a central cup or screw holes, and therefore limiting use for complex revision surgery. More recently, modular dual-mobility (MDM) constructs have been developed (for example MDM by Stryker Ltd, Berkshire, UK, and the Delta TT system by Lima Orthopaedics UK Ltd, Herts, UK), where a modular cobalt–chromium (CoCr) liner sits within the traditional titanium acetabular shell. This adds the advantages of the traditional porous metal shell, with its options for supplementary acetabular screw fixation, use of metal augments, and ability to visualize complete seating of the cup through the screw holes. However, the combination of the CoCr liner and titanium shell creates a new interface for potential fretting corrosion and subsequent adverse reaction to metal debris (ARMD).
Adverse reaction to metal debris

ARMD is an umbrella term used to describe joint failures associated with pain, a large sterile effusion of the hip and/or macroscopic necrosis/‘metallosis’. Diagnosis is based on clinical suspicion, raised serum metal ion levels, magnetic resonance imaging (MRI), and ultimately intraoperative and histological findings. ARMD was first noted in metal-on-metal (MoM) THR, occurring between bearing surfaces and also as a result of fretting corrosion at the modular neck–head junction. For the purposes of this review, ARMD encompasses other terms found in the literature such as ‘metallosis’, pseudotumour, adverse local tissue reaction (ALTR), and aseptic lymphocyte-dominated vasculitis-associated lesion (ALVAL).

Aim

The aim of this systematic review was to find and review all relevant studies to establish outcomes following THR with an MDM construct, with a particular focus on ARMD.

Methods

Study criteria

Inclusion criteria were all clinical studies of adult patients receiving an MDM hip replacement as either a primary or revision procedure. Exclusion criteria were studies which were not specifically on MDM constructs or which grouped MDM with other hip replacements in analysis, case reports, review articles, expert opinion pieces, biomechanical studies, animal studies, in vitro studies, book chapters, conference abstracts, and non-English-language articles. In cases of multiple articles reporting on the same patient cohort, the latest article was included and the others excluded.

Outcome measures

The primary outcome measure was the rate of ARMD requiring revision surgery, as defined by primary studies. Secondary outcome measures were mean postoperative cobalt (Co) and chromium (Cr) levels, proportion of patients with raised metal ion levels, evidence of corrosion on implant analysis, clinical hip scores, dislocation rate, and revision rate.

Literature search

A systematic search of the literature was undertaken on 7 June 2020. The full search strategy is available in Appendix 1. Search terms included variations on hip or acetabular replacement in combination with modular dual mobility, with no date restriction. The search was performed in Medline, EMBASE, CINAHL, Cochrane Library, and Prospero. Reference lists of selected studies were also manually searched. A proposal for the systematic review was submitted to PROSPERO in May 2020 (CRD42020177033).

Data extraction and risk of bias assessment

Two reviewers (JF and SS) independently screened titles and abstracts to identify potentially useful articles. Disputes were settled by a third reviewer (NS). Data extracted included study design, type of arthroplasty (primary/revision), indication for arthroplasty, mean follow-up, implant manufacturer, femoral head material, use of supplementary acetabular screws, dislocation rate, revision rate, ARMD rate, mean serum metal ion values, and proportion of patients with raised serum metal ion measurements (Co or Cr ≥ 1 μg/L, and Co or Cr ≥ 7 μg/L).

A ‘normal’ cut-off value of Co or Cr ≥ 1 μg/L was chosen due to it being the most common amongst included studies. If the incidence of cases above this value was not expressed, the most conservative estimate was taken from the range. For example, if results were expressed as ‘mean Co 0.85 range 0.5–2.3 μg/L, Cr 0.61 range 0.5–1.3 μg/L’, the study would be counted as having one case of Co or Cr levels ≥ 1 μg/L, as potentially one case could have been responsible for both upper limit values. If studies included more than one postoperative serum metal ion measurement (e.g. at 1 and 2 years postoperatively), the latest value was used.

Risk of bias of included studies was assessed using the Methodological Index for Non-Randomised Studies (MINORS) scoring system; a validated tool for assessing study quality which gives a score out of 16 for non-comparative, and 24 for comparative studies. Again, two reviewers independently scored each article (JF and SS) with a third to settle disputes (NS).

Statistical analysis

Meta-analysis was undertaken to synthesise values for (a) the incidence of ARMD requiring revision surgery (b) incidence of dislocation (c) incidence of revision (d) incidence of a serum cobalt or chromium level ≥ 1 μg/L (e) incidence of a serum cobalt or chromium level ≥ 7 μg/L (f) mean serum values of cobalt (g) mean serum values of chromium. Given that the data are observational, and that there were substantial differences in population, type of implant, femoral head material, length of follow-up, primary or revision procedure, and indication for surgery, a random-effects approach was undertaken for all analyses. For analyses (a) to (e) the data are proportions of patients who have a relatively rare outcome and values of zero are common. For these reasons a random intercept logistic regression model was used, with confidence intervals derived using the t distribution. For analysis (a), only cohort studies with detailed clinical follow-up were
The initial search yielded 99 articles. After screening for duplicate publications, 46 were excluded, leaving 53. Screening by title and abstract excluded a further 21, leaving 32 articles which underwent full-text review. Out of these, 16 were identified for overall inclusion \(^{16-31}\) (Fig. 1 \(^{32}\)), with meta-analysis performed on specific subsets as described below.

Data on dislocation were only reported in six studies, with 14 reported in 1109 cases. The estimated median incidence of dislocation was 0.8% (95% CI 0.1 – 4.3%).
Revision rates were reported in eight studies, with 70 revisions out of 1212, giving an estimated median incidence of 3.3% (95% CI 0.9 – 11.7%).

The mean postoperative serum cobalt level across all studies was calculated to be 0.81 μg/L (95% CI 0.11 – 1.51 μg/L), and chromium was 0.77 μg/L (95% 0.2 – 1.34 μg/L), both from 279 cases in seven studies. Estimated median incidence of a serum cobalt or chromium ion measurement ≥1 μg/L was 7.9% (95% CI 3.5 – 16.8%) and ≥7 μg/L was 1.8% (95% CI 0.7 – 4.2%). Table 2 summarizes study metal ion levels with relevant study characteristics.

No studies reported a statistically significant correlation between raised serum metal ions and lower clinical hip function scores, which were universally good across all 12 cohort studies.

### Table 1. Summary of all study characteristics, grouped by study type. A dash (–) denotes data that were unreported. An asterisk (*) denotes data excluded from meta-analysis, e.g. case series are unable to contribute data on incidence

| Study                          | Study design (single centre unless specified) | Primary or revision THR | Number of cases | Average follow-up (years) | Implant (company) | Mean age (years) | Mean BMI (kg/m²) | Dislocations, n (%) | Revisions, n (%) | ARMD, n (%) |
|-------------------------------|---------------------------------------------|-------------------------|----------------|---------------------------|-------------------|----------------|----------------|-------------------|-----------------|------------|
| With serum metal ion measurements | Cross-sectional study | Revision | 37 | 5.1 | Delta TT System (Lima) | 63.7 | 26.5 | – | – | 0 |
| Markel et al, 2019 ‡ 19       | Prospective cohort, non-comparative         | Primary | 39 | 2 | MDM (Stryker) | 61.7 | 28.4 | – | – | 0 |
| Chalmers et al, 2019 ‡ 20     | Prospective cohort, non-comparative         | Both | 24 | 4 | MDM (Stryker) | 63.0 | 31.0 | – | Excluded | 0 |
| Nam et al, 2019 ‡ 12          | Prospective cohort, non-comparative         | Primary | 43 | 2 | MDM (Stryker) | 52.6 | 27.9 | – | 0 | 0 |
| Diamond et al, 2018 ‡ 23      | Retrospective cohort, non-comparative       | Revision | 60 | 3.21 | MDM (Stryker) | 65.5 | 30.9 | – | 6 (10%) | 2 (3.3%) |
| Barlow et al, 2017 ‡ 24       | Prospective case-series of various well functioning primary THRs | Primary | 20 | 1.3 | MDM (Stryker) | 66.8 | – | Excluded | Excluded | Excluded |
| Matsen Ko et al, 2020 ‡ 27    | Retrospective cohort, non-comparative       | Primary | 100 | 2.3 | MDM (Stryker) | – | – | 1 | 0 | 2 |
| Dubin et al, 2019 ‡ 17        | Retrospective cohort: MDM vs. ADM           | Primary | 287 | 2.86 | MDM (Stryker) | 67.9 | 29.3 | 0 | 5 (1.7%) | 0 |
| Li et al, 2019 ‡ 18           | Retrospective cohort: MDM vs. conventional conventional | Revision | 94 | 3.15 | MDM (Stryker) | 63.6 | 29.6 | 2 (2.13%) | 9 (9.57%) | 1 (1%) |
| Huang et al, 2019 ‡ 21        | Retrospective cohort, multi-centre, non-comparative | Revision | 315 | 3.3 | MDM (Stryker) | 65.8 | 31.4 | 9 (3.8%) | 30 (9.5%) | 0 |
| Sutter et al, 2017 ‡ 23       | Retrospective cohort, non-comparative       | Revision | 64 | 3.17 | MDM (Stryker) | 59.0 | 29.4 | 2 (3.1%) | 18.80% | 1 (1.6%) |
| Harwin et al, 2017 ‡ 24       | Retrospective cohort, multi-centre, non-comparative | Primary | 249 | 3.3 | MDM (Stryker) | 66.0 | 34.0 | 0 | 2 (0.8%) | 0 |
| Implant retrieval analyses    | Implant retrieval case series: MDM         | Both | 12 | 2.16 | MDM (Stryker) | – | 26.0 | N/A | N/A | * |
| Kolz et al, 2020 ‡ 20         | –                                           | – | 18 | 1.12 | MDM (Stryker) | 70.5 | 30.0 | N/A | N/A | * |
| Lombardo et al, 2019 ‡ 21     | Implant retrieval analysis: ADM vs. ADM     | Both | 18 | 1.25 | MDM (Stryker) | 64.0 | 27.0 | N/A | N/A | * |
| Tarity et al, 2017 ‡ 28       | Implant retrieval analysis: MDM vs. MoM     | Both | 18 | 1.25 | MDM (Stryker) | 64.0 | 27.0 | N/A | N/A | * |
| Radiological                 | Retrospective cohort: MDM                   | Primary | 551 | – | MDM (Stryker) | 67.9 | 28.3 | – | – | – |

Notes. THR, total hip replacement; BMI, body mass index; ARMD, adverse reaction to metal debris; MDM, modular dual-mobility; ADM, ‘anatomical’ dual-mobility; MoM, metal-on-metal.
replacements on retrospective review of the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man.\textsuperscript{33} Additionally, included studies had relatively short mean follow-up periods, ranging from 1.1 to 5.1 years; whereas revisions for ARMD in MoM hips are performed on average 5.6 years after index surgery. The incidence is therefore a concern and requires further study. Surgeons should be aware of the potentially increased rate of ARMD as an additional risk when considering use of these constructs during preoperative planning. More reassuringly, the rate of ARMD is substantially lower than the 3.7% estimated in MoM hip replacements.\textsuperscript{33}

The proportion of patients who had a Co or Cr measurement of ≥1 μg/L postoperatively was 7.9% (95% CI 3.5 – 16.8%). The clinical significance of these values is unclear as there was no correlation clinically within studies, and additionally there are no established ‘normal’ metal ion levels following THR.\textsuperscript{24} Here, the cut-off value of ≥ 1 μg/L was selected as it was the most commonly used. For MoM hip replacements the MHRA (Medicines & Healthcare Products Regulatory Agency, UK regulatory body) advise a cut-off value of ≥ 7 μg/L for either cobalt or chromium.\textsuperscript{34}

This threshold has a high specificity (89%) but low sensitivity (52%) for ARMD.\textsuperscript{31} From our meta-analysis, 1.8% (95% CI 0.7 – 4.2%) of patients had Co or Cr levels above this threshold. More recently, implant-specific cut-offs for MoM hip replacements have been suggested, for example a cobalt level of ≥ 2.15 μg/L for a unilateral Birmingham MoM THR,\textsuperscript{36} suggesting that it may not be appropriate to use one blanket threshold for all designs. Two recent studies specifically on standard metal-on-polyethylene (MoP) constructs reported > 90% sensitivity and specificity using a threshold cut-off of cobalt ≥ 1.0 μg/L for diagnosing ARMD, likely as a result of trunnion corrosion.\textsuperscript{37,38}

The estimated incidence of ARMD following MDM hip replacement is 0.3% (95% CI 0.1 – 1.8%). This is higher than the 0.032% reported in all non-MoM primary hip

**Discussion**

The estimated incidence of ARMD following MDM hip replacement is 0.3% (95% CI 0.1 – 1.8%). This is higher than the 0.032% reported in all non-MoM primary hip

---

**Table 2. Serum metal ion levels by study, with relevant characteristics such as femoral head material and use of acetabular screws. An asterisk (*) is used to indicate where individual data were not specified, necessitating a conservative estimate (see Methods)**

| Study | Primary or revision THR | Number | Implant | Femoral head material | Acetabular screw fixation | ARMD, n (%) | Average serum metal ion levels (μg/L), mean unless specified | Number of cases with Co or Cr ≥ 1 μg/L | Number of cases with Co or Cr ≥ 7 μg/L |
|-------|------------------------|--------|---------|-----------------------|---------------------------|-------------|----------------------------------------------------------|--------------------------------------|---------------------------------------|
| Civinini et al, 2020\textsuperscript{16} | Revision 37 | Delta TT System (Lima) MDM (Stryker) | CoCr | All pts (mean 4.2 screws, range 2–7) | 0 | Co 1.99 (95% CI 0.81 – 3.17, range 0.07 – 16.05), Cr 2.08 (95% CI 0.9 – 3.2, range 0.02 – 11.8) | 11 (29.7%) | 2* |
| Markel et al, 2019\textsuperscript{19} | Primary 39 | MDM (Stryker) | Ceramic | – | 0 | Co 0.63 (SD 0.36), Cr 0.63 (SD 0.38) | 4 (10.3%) | 0 |
| Chalmers et al, 2019\textsuperscript{20} | Both 24 | MDM (Stryker) | Ceramic | All patients | 0 | Co 0.3 (range 0.2 – 0.6), Cr 0.76 (0.1 – 12.0) | 1 (4.2%) | 1 (4.2%) |
| Nam et al, 2019\textsuperscript{22} | Primary 43 | MDM (Stryker) | 14 CoCr, 29 ceramic | – | 0 | Co 0.16 (SD 0.23; range 0.04 – 0.96), Cr 0.14 (SD 0.053; range 0.07 – 0.26) | 0 | 0 |
| Diamond et al, 2018\textsuperscript{23} | Revision 60 | MDM (Stryker) | 59 CoCr, 1 ceramic | ‘Most commonly, 2 or 3’ | 2 (3.3%), both recurrent | Median Co 0.42 (range 0.21 – 9.42), Cr 0.4 (range 0.1 – 6.1) | 2* (3.3%) | 1 (1.7%) |
| Barlow et al, 2017\textsuperscript{24} | Primary 20 | MDM (Stryker) | 10 CoCr, 10 ceramic | – | 0 | Co 0.85 (SD 0.54, range 0.5 – 2.3), Cr 0.61 (SD 0.26, range 0.5 – 1.3) | 1* (5%) | 0 |
| Matsen Ko et al, 2016\textsuperscript{27} | Primary 100 | MDM (Stryker) | 99 CoCr, 1 ceramic | – | 2 | ‘Average’ Co 0.7 (range 0.0 – 7.0), Cr 0.6 (range 0.1 – 2.7) | 9 (9%) | 1 (1.0%) |

Notes. THR, total hip replacement; ARMD, adverse reaction to metal debris; Co, cobalt; Cr, chromium; MDM, modular dual-mobility.
other hand there are studies that report no correlation between preoperative serum metal ion levels and intraoperative scoring for severity of ARMD. Considering this conflicting evidence, currently metal ion levels should be regarded as an unproven surrogate marker for ARMD, and therefore no strong conclusions can be drawn from the mean postoperative Co value of 0.81 μg/L (95% CI 0.11 – 1.51 μg/L). The figure might be useful as a reference value against which further work can be compared.

Regarding the source of metal-based debris, results of implant retrieval studies were also varied. Kolz et al found significant material loss on the metal liner in all 12 of their cases, but those revised for ARMD (n = 3) did not show significantly higher fretting corrosion scores. The two other studies found no significant increase in fretting corrosion of MDM compared to MoM or ADM constructs (n = 36), with no cases revised due to ARMD. Whilst this is somewhat reassuring, there was one reported case of macroscopic damage on the backside of the inner metal liner seemingly from acetabular screw heads (Fig. 3). This occurrence was also reported in the included cohort study by Sutter et al, where, during the revision procedure for pain and raised serum chromium ions (7.3 μg/L), metal staining of soft tissues and mild scuffing from loose screw heads on the backside of the metal liner was noted, without visible wear of the femoral component. Unfortunately, the usage of acetabular screws is sparsely reported in the literature (Table 2), limiting further conclusions. Another theory is provided by the radiographic study of 551 cases, finding that 5.8% of MDM liners were malseated on retrospective evaluation. Subsequent in vitro modelling in the same study suggested that liner malseating can lead to lower fretting onset loads. Taken together, these results corroborate findings by Kolz et al describing three different patterns of wear, and suggest that debris generation in MDM constructs is likely a combination of intrinsic (component design) and extrinsic (surgical) factors. Surgeons, if choosing to use an MDM construct, should therefore take extra care to ensure that screw heads are completely recessed within the holes of the acetabular shell, and the metal liner is properly seated. We recommend a low threshold for postoperative imaging and serum metal ion testing.

The estimated median incidence of dislocation was 0.8% (95% CI 0.2 – 2.9). Both primary and revision procedures were grouped together in this analysis due to low number of cases. The results broadly align with the 0.46–3% quoted in meta-analyses of all DM constructs specifically examining dislocation rate, and is in accordance with findings that DM constructs can be used to minimize risk of dislocation following THR.

**Limitations**

The main limitation of this review is that the primary evidence is of low quality with high risk of bias, mostly comprising small, clinically heterogeneous, retrospective cohort studies. The main methodological weakness of studies was a lack of control against confounding from fretting corrosion at the head–neck taper junction; the majority (12 of 16) of the studies either used CoCr femoral heads, made no distinction between cases using CoCr or ceramic heads in analysis, or did not report femoral head material. The use of ARMD requiring revision surgery as the primary outcome measure is also a limitation as it does not take into account non-operatively managed cases. This is especially relevant considering the relatively short follow-up period and possibility of publication bias; the incidence of 0.3% is therefore likely an under-estimate.

For metal ion levels, source data were not obtained from individual studies. Two of seven studies did not express incidence of cases with either Co or Cr measurements ≥ 1 μg/L, and conservative estimates had to be taken from the range, also likely resulting in an under-estimate.

More broadly, meta-analysis of observational data should not be considered as accurate as meta-analysis of trial data. The nature of cohort and cross-sectional studies means that results are vulnerable to confounding, as mentioned above, that cannot be adjusted for in this analysis. Results should therefore be considered to be the best available estimates, but still potentially confounded. Additionally, the choice to use a random-effects model is appropriate given the heterogeneous data, but this can increase vulnerability to publication bias.

**Recommendations for further work and conclusion**

There is a need for a large comparative study of patients with MDM versus ADM hip replacements using ceramic femoral heads. If a cohort with entirely ceramic heads...
is not possible, differing femoral head materials should be grouped separately in analysis. A suitable alternative design would be MDM with a CoCr femoral head versus conventional MoP hip replacements. Supplementary screw use with the MDM acetabular component should be reported. Outcome measures should include clinical hip function scores, pre and postoperative serum metal ion measurements, with MRI where possible. Optimum average follow-up would be five years or longer. Full summary statistics should be reported to prevent future meta-analyses having to estimate values from the range.

ARMD is a rare but significant complication following total hip replacement using an MDM construct. Its incidence appears higher than that reported in non-MoM hip replacements, but lower than that of MoM hip replacements. MDM hip replacements are associated with raised serum metal ion levels postoperatively. There is no evidence thus far that these elevations are associated with increased risk of ARMD or correlate with worse clinical hip function scores. There are mixed reports of fretting corrosion on the backside of the modular liner from the acetabular shell and/or screws. Malseating of components is a likely contributing factor. However, study quality is low and results are open to confounding, particularly from trunnion corrosion. Pending further work, if using MDM constructs, surgeons should carefully weigh the possibility of increased risk of ARMD against its benefits as part of the normal preoperative planning decision making process. If MDM components are used, great care should be taken to correctly seat acetabular screws and the liner within the acetabular shell.

**AUTHOR INFORMATION**

1Bristol Royal Infirmary, University Hospitals Bristol NHS Trust, Bristol, UK.
2Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
3Southland Teaching Hospital, Invercargill, New Zealand.

Correspondence should be sent to: Jonathan French, Bristol Royal Infirmary, Upper Maudlin Street, Bristol, BS2 8HW, UK.
Email: jmf@hotmai.co.uk

**ACKNOWLEDGEMENTS**

We would like to thank the UH Bristol Library for their valuable assistance in the literature search, Dr Erin Baker for permission to reproduce her study’s photograph, and the National Institute for Health Research for supporting the research time of PB.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available for this paper at https://online.boneandjoint.org.uk/doi/suppl/10.1302/2058-5241.6.200146

**ICMJE CONFLICT OF INTEREST STATEMENT**

The authors declare no conflict of interest relevant to this work.

**FUNDING STATEMENT**

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

**OPEN ACCESS**

© 2021 The author(s) This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

**REFERENCES**

1. Fender D, Harper WM, Gregg PJ. Outcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip register. J Bone Joint Surg Br 1999;81:577–581.
2. Kwon MS, Kuskowski M, Mulhall KJ, Macaulay W, Brown TE, Saleh KJ. Does surgical approach affect total hip arthroplasty dislocation rates? Clin Orthop Relat Res 2006;447:34–38.
3. Blom AW, Rogers M, Taylor AH, Pattison G, Whitehouse S, Bannister GC. Dislocation following total hip replacement: the Avon Orthopaedic Centre experience. Ann R Coll Surg Engl 2008;90:658–662.
4. De Martino I, D’Apolito R, Soranoglou VG, Poultsides LA, Sculco PK, Sculco TP. Dislocation following total hip arthroplasty using dual mobility acetabular components: a systematic review. Bone Joint J 2017;99-B:18–24.
5. Charnley J. The long-term results of low-friction arthroplasty of the hip performed as a primary intervention. J Bone Joint Surg Br 1972;54:61–76.
6. Plummer DR, Haughom BD, Della Valle CJ. Dual mobility in total hip arthroplasty. Orthop Clin North Am 2014;45:1–8.
7. Neri T, Philippot R, Klasan A, et al. Dual mobility acetabular cups for total hip arthroplasty: advantages and drawbacks. Expert Rev Med Devices 2018;15:835–845.
8. Darrith B, Courtney PM, Della Valle CJ. Outcomes of dual mobility components in total hip arthroplasty: a systematic review of the literature. Bone Joint J 2018;100-B:71–79.
9. Hartzler MA, Abdel MP, Sculco PK, Taunton MJ, Pagnano MW, Hanssen AD. Otto Aufranc Award: dual-mobility constructs in revision THA reduced dislocation, rerevision, and reoperation compared with large femoral heads. Clin Orthop Relat Res 2018;476:293–301.
10. Waterson HB, Whitehouse MR, Greidanus NV, Garbuz DS, Masri BA, Duncan CP. Revision for adverse local tissue reaction following metal-on-polyethylene total hip arthroplasty is associated with a high risk of early major complications. Bone Joint J 2018;100-B:720–724.
11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 2003;73:712–716.
12. Stijnen T, Hamza TH, Özdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med 2010;29:3046–3067.
13. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014;14:135.
Appendix 1. Healthcare Databases Advanced Search (HDAS) strategy

Search terms used in HDAS:
1. (hip OR acetabul*) ADJ4 (replac* OR surg*),ti,ab
2. (hip OR acetabul*) ADJ4 arthroplast*,ti,ab
3. (hip OR acetabul*) ADJ4 implant*,ti,ab
4. (hip OR acetabul*) ADJ4 prosthesis),ti,ab
5. exp “ARTHROPLASTY, REPLACEMENT”/
6. (1 OR 2 OR 3 OR 4 OR S)
7. (modular dual mobility),ti,ab
8. (modular dual-mobility),ti,ab
9. (7 OR 8)
10. (6 AND 9)
Appendix 2. All other forest and funnel plots from meta-analysis

|                | RE Model                                                                 |
|----------------|---------------------------------------------------------------------------|
| Mean Cobalt    |                                                                           |
| Civinini et al, 2020 | 1.99 [0.81, 3.17]                                                     |
| Markel et al, 2019    | 0.63 [0.52, 0.74]                                                      |
| Chalmers et al, 2019  | 0.30 [0.26, 0.34]                                                      |
| Nam et al, 2019       | 0.16 [0.09, 0.23]                                                      |
| Diamond et al, 2018   | 2.62 [1.35, 3.89]                                                      |
| Barlow et al, 2017    | 0.85 [0.61, 1.09]                                                      |
| Matsen Ko et al, 2016 | 0.70 [0.43, 0.97]                                                      |
| Mean Chromium       |                                                                           |
| Civinini et al, 2020 | 2.08 [0.93, 3.23]                                                      |
| Markel et al, 2019    | 0.63 [0.51, 0.75]                                                      |
| Chalmers et al, 2019  | 0.76 [-0.46, 1.98]                                                     |
| Nam et al, 2019       | 0.14 [0.13, 0.15]                                                      |
| Diamond et al, 2018   | 1.75 [0.92, 2.58]                                                      |
| Barlow et al, 2017    | 0.61 [0.50, 0.72]                                                      |
| Matsen Ko et al, 2016 | 0.60 [0.50, 0.70]                                                      |

|                | RE Model                                                                 |
|----------------|---------------------------------------------------------------------------|
| Mean Chromium  |                                                                           |
| Civinini et al, 2020 | 0.77 [0.20, 1.34]                                                      |
| Markel et al, 2019    | 0.002 [0.000, 0.027]                                                     |
| Li et al, 2019        | 0.021 [0.005, 0.081]                                                     |
| Huang et al, 2019     | 0.029 [0.015, 0.054]                                                     |
| Sutter et al, 2017    | 0.031 [0.008, 0.117]                                                     |
| Harvin et al, 2017    | 0.002 [0.000, 0.031]                                                     |
| Matsen Ko et al, 2016 | 0.010 [0.001, 0.068]                                                     |

Dislocation rate

|                | RE Model                                                                 |
|----------------|---------------------------------------------------------------------------|
| Dubin et al, 2019 | 0.008 [0.001, 0.043]                                                     |

(continued)
Appendix 2 (continued)

| Dislocation rate | Mildly raised metal ion levels (<1) | Significantly raised metal ion levels (>7) | Revision rate |
|------------------|--------------------------------------|------------------------------------------|--------------|
| Matsen Ko et al, 2016 | 0.297 [0.173, 0.461] | Civinini et al, 2020 | 0.054 [0.014, 0.192] |
| Markel et al, 2019 | 0.103 [0.039, 0.243] | Markel et al, 2019 | 0.012 [0.001, 0.171] |
| Chalmers et al, 2019 | 0.042 [0.006, 0.244] | Chalmers et al, 2019 | 0.04 [0.006, 0.18] |
| Nam et al, 2019 | 0.001 [0.00, 0.157] | Nam et al, 2019 | 0.011 [0.001, 0.157] |
| Diamond et al, 2018 | 0.125 [0.031, 0.386] | Diamond et al, 2018 | 0.062 [0.009, 0.335] |
| Barlow et al, 2017 | 0.012 [0.001, 0.282] | Barlow et al, 2017 | 0.024 [0.001, 0.287] |
| Matsen Ko et al, 2016 | 0.090 [0.047, 0.164] | Matsen Ko et al, 2016 | 0.010 [0.001, 0.068] |
| RE Model | 0.079 [0.029, 0.200] | RE Model | 0.018 [0.006, 0.052] |
| 0.000 | 0.200 | 0.000 | 0.000 |

(continued)
Appendix 2. Table showing individual risk of bias (MINORS) scores

| MINORS 1 | MINORS 2 | MINORS 3 | MINORS 4 | MINORS 5 | MINORS 6 | MINORS 7 | MINORS 8 | MINORS 9 | MINORS 10 | MINORS 11 | MINORS 12 | Total |
|----------|----------|----------|----------|----------|----------|----------|----------|----------|-----------|-----------|-----------|--------|
| Kolz et al, 2020 | 2 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 8 |
| Romero, 2020 | 2 | 2 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 10 |
| Civinni et al, 2020 | 2 | 2 | 1 | 2 | 0 | 2 | 1 | 0 | 2 | 2 | 2 | 2 | 17 |
| Dubin et al, 2019 | 2 | 1 | 2 | 2 | 0 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 17 |
| Li et al, 2019 | 2 | 2 | 2 | 2 | 0 | 1 | 0 | 1 | 2 | 2 | 1 | 2 | 17 |
| Markel et al, 2019 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 7 |
| Chalmers et al, 2019 | 1 | 2 | 2 | 2 | 0 | 1 | 1 | 0 | 0 | 9 |
| Huang et al, 2019 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 7 |
| Nam et al, 2019 | 2 | 0 | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 9 |
| Lombardo et al, 2019 | 1 | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 2 | 0 | 1 | 2 | 11 |
| Diamond et al, 2018 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 5 |
| Sutter et al, 2017 | 1 | 2 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 6 |
| Harvin et al, 2017 | 2 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 7 |
| Tarity et al, 2017 | 2 | 1 | 2 | 2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 14 |
| Barlow et al, 2017 | 2 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 2 | 13 |
| Matsen Ko et al, 2016 | 1 | 2 | 1 | 1 | 0 | 1 | 2 | 0 | 0 | 8 |